Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
), and waist circumference (WMD -5.32 cm, 95% CI -9.13 to -1.51 cm). More patients treated with orforglipron than placebo achieved a weight loss of ≥ 5% (RR 3.31, 95% CI 2.23-4.93), ≥ 10% (RR 5.24, 95% CI 2.07-13.31), and ≥ 15% (RR 9.53, 95% CI 1.26-71.89). The most common adverse events were related to the gastrointestinal tract. In this meta-analysis, the use of once-daily oral orforglipron by adult patients was associated with a significant decrease in body weight, as compared with placebo, with an increase in non-severe gastrointestinal adverse events. Phase 3 RCTs are expected to shed further light on the efficacy and safety of once-daily oral orforglipron over the long term.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meta-analyses of randomized controlled trials corroborate these findings, demonstrating pooled weight reductions of 9–12% relative to placebo at 26–72 weeks [49,50].”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [50]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Shi, Q., Wang, Y., Hao, Q., Vandvik, P. O., Guyatt, G., Li, J., Chen, Z., Xu, S., Shen, Y., Ge, L., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01640-8 · Cited by 279
RetractedThe PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“DerSimonian and Laird random-effects models were used for all endpoints (16).”
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787 · cited 12×
“The main domains responsible for reducing the quality of evidence of the outcomes were risk of bias, inconsistency of results due to heterogeneity, and imprecision due to the small number of RCTs included in the statistical analysis.”
InfluentialGRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285 · cited 1×
“The quality of evidence was assessed according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) guidelines (18,19).”
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003583 · Cited by 5,148 · cited 1×
“This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (12).”
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 3×
“Recently introduced as an anti-obesity medication, semaglutide 2.4 mg demonstrated a placebo-adjusted weight reduction of 12.4%, with almost one-third of individuals achieving a weight loss of 20% or more (21,22).”
Influential
Research works printed but not linked: 3
- 4. World Obesity Federation. World Obesity Atlas 2023. Available from: https://data.worldobesity.org/publications/WOF-Obesity-Atlas-V5.pdf. Accessed in: November 8, 2023.
- 17. Higgins JP, Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane. 2022. Available from: www.training.cochrane.org/ handbook.
- 23. Eli Lilly and Company's. FDA Approves Lilly's ZepboundTM (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems. Available from: https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight. Accessed in: November 11, 2023.
Cited by
Gaggini, M., Sabatino, L., Suman, A. F., Chatzianagnostou, K., & Vassalle, C. (2025) · Cells · doi:10.3390/cells14050387 · Cited by 35
“…meta-analysis investigated the effects of once-daily oral orforglipron on weight and metabolic markers in adults; the results showed the efficacy of this drug on body weight, as compared with placebo, although an increase in non-severe gastrointestinal adverse events was also observed [127].”
Saldívar-Cerón, H. I., Vargas-Camacho, J. A., León‐Cabrera, S., Briseño-Díaz, P., Castañeda-Ramírez, A. E., Muciño-Galicia, A. E., & Díaz-Domínguez, M. R. (2025) · Scientia Pharmaceutica · doi:10.3390/scipharm93020026 · Cited by 25
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
“Meta-analyses of randomized controlled trials corroborate these findings, demonstrating pooled weight reductions of 9–12% relative to placebo at 26–72 weeks [49,50].”
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare
Bhat, S., Fernandez, C. J., Lakshmi, V., & Pappachan, J. M. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i8.107991 · Cited by 9
Zhou, J., Wang, F., & Li, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1646956 · Cited by 3
Metadata
- Authors
- Lütkemeyer, C., Pasqualotto, E., Ferreira, R. O. M., Chavez, M. P., Petris, I., Santos, H. V. D., Wille, J. M., Hohl, A., Ronsoni, M. F., & Sande-Lee, S. V. D.
- Affiliations
- Universidade Federal de Santa Catarina (BR)
- Universidade Federal do Paraná (BR)
- ORCID
- Venue
- Archives of Endocrinology and Metabolism
- Published
- 2024
- Volume
- 68
- Pages
- e230469-e230469
- ISSN
- 2359-3997 (ISSN-L)
- 2359-4292
- PMC
- PMC11460968
- OpenAlex
- W4403180344
- Cited by
- 10
- References
- 35
- Citations by year
- 2026: 5 · 2025: 5
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- other-oa
- Locations
- Archives of Endocrinology and Metabolism (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- orforglipron, GLP-1 receptor agonists, weight loss, body weight, waist circumference, metabolic biomarkers, gastrointestinal adverse effects, obesity treatment
- MeSH terms
- Administration, Oral, Body Weight, Drug Administration Schedule, Humans, Obesity, Oxadiazoles, Biomarkers, Body Mass Index, Randomized Controlled Trials as Topic, Fluorine Compounds, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.20945/2359-4292-2023-0469
- The paper
- Lütkemeyer, C., Pasqualotto, E., Ferreira, R. O. M., Chavez, M. P., Petris, I., Santos, H. V. D., Wille, J. M., Hohl, A., Ronsoni, M. F., & Sande-Lee, S. V. D. (2024). Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials. Archives of Endocrinology and Metabolism. https://doi.org/10.20945/2359-4292-2023-0469
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.